Saturday, January 25, 2025

CATEGORY

Roche

Roche Integrates Mass Spectrometry into Clinical Labs with cobas Mass Spec

Key Takeaways • The cobas Mass Spec solution enhances early detection of therapeutic responses in hormone therapy. • Automation and standardization reduce operational variability across laboratories. •...

Roche Details Four-Year Efficacy of Lunsumio in Relapsed Follicular Lymphoma

Key TakeawaysLunsumio significantly extends progression-free survival in relapsed follicular lymphoma. The treatment maintains a favorable safety profile over four years of use. Patients...

Roche Announces Breakthrough Lymphoma Treatments with Durable Remissions

Key TakeawaysFixed-duration therapies like Columvi and Lunsumio provide sustained remissions, enhancing long-term patient outcomes. Subcutaneous Lunsumio offers a practical alternative to intravenous treatments,...

Roche Elevates Polivy as Standard Treatment for New DLBCL Cases

Key TakeawaysPolivy's combination therapy could redefine first-line treatment standards. Long-term data supports broader clinical adoption and guideline updates. Future studies may investigate Polivy's...

Roche Submits Columvi plus GemOx for FDA Approval in Aggressive Lymphoma

Key TakeawaysColumvi plus GemOx demonstrated a statistically significant and clinically meaningful improvement in overall survival. The fixed-duration treatment offers a timely option post-diagnosis...

Roche Shares Latest Results from SKYSCRAPER-01 Phase III Trial

Roche has unveiled new findings from its Phase III SKYSCRAPER-01 study, marking a significant milestone in the development of innovative treatments. The comprehensive analysis...

Roche Acquires Poseida Therapeutics for $1 Billion Enhancing CAR-T Therapy Portfolio

Roche has finalized a definitive merger agreement to obtain Poseida Therapeutics, a San Diego-based biopharmaceutical company specializing in donor-derived CAR-T cell therapies. The acquisition,...

Roche Showcases Cutting-Edge Advances in Hematology at ASH 2024

User-Usable Inferences - Polivy demonstrates potential in combination therapies for DLBCL, showing positive survival trends. - Lunsumio and Columvi offer long-lasting remission and manageable safety profiles. -...

Itovebi Regimen Shows Promise in Breast Cancer Treatment

Key TakeawaysEarly testing for PIK3CA mutations can identify patients who may benefit from Itovebi-based therapy. The Itovebi regimen offers a promising first-line treatment...

Roche’s Innovative Blood Test Offers New Hope for Alzheimer’s Diagnosis

Key TakeawaysThe Elecsys Amyloid Plasma Panel shows high accuracy in ruling out Alzheimer's, reducing the need for invasive tests. A negative result from...

Vabysmo Shows Promising Results for Underrepresented Groups in DME Treatment

A recent groundbreaking study has highlighted significant advancements in treating diabetic macular edema (DME) for African American, Black, Hispanic, and Latino populations. Conducted by...

Roche’s Evrysdi Shows Promising Results in Early SMA Treatment for Infants

Roche has unveiled promising data from its RAINBOWFISH study, highlighting Evrysdi's efficacy and safety in treating spinal muscular atrophy (SMA) in infants. This groundbreaking...

Majority of Children with SMA Treated with Roche’s Evrysdi Achieve Motor Milestones, Two-Year Data Show

Key TakeawaysRoche’s Evrysdi® (risdiplam) demonstrated that the majority of children with spinal muscular atrophy (SMA), treated pre-symptomatically before six weeks of age, were...

FDA Approves Roche’s Itovebi for Advanced HR-Positive, HER2-Negative Breast Cancer with PIK3CA Mutation

Key TakeawaysItovebiâ„¢ (inavolisib) gains FDA approval for treating PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing over double the progression-free survival compared to standard...

Gazyva/Gazyvaro Offers New Hope for Lupus Nephritis Patients: Key Findings from Roche’s Phase III REGENCY Study

Key TakeawaysGazyva/Gazyvaro significantly improves complete renal response rates in lupus nephritis patients compared to standard therapy alone. Secondary endpoints show a successful reduction...

Latest news